Menu
Recruiting NCT07231757

The RADIANCE CED Study

Observational Hypertension Cardiovascular Diseases Vascular Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System).
Who it may be relevant to
Registry conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases. Basic parameters: from 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Recor Paradise System™ Hypertension Coverage With Evidence Development Study

Overview

The RADIANCE CED study is a prospective observational study designed to evaluate the long-term effectiveness of ultrasound renal denervation in lowering blood pressure among patients with uncontrolled hypertension. Data will be collected from electronic health records (EHRs) of Medicare-eligible patients to support generalizability of outcomes to the broader Medicare population. Individual hospital enrollment is not required for this study and IRB exemption has been received by sponsor.

Interventions

  • Device Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System)
    A catheter-based system that delivers ultrasound energy to the renal sympathetic nerves.

Primary outcome measures

  • Assessment for Changes in Blood Pressure [Time frame: November 2025 - December 2029]
Secondary outcome measures (2)
  • Occurrence of Adverse Cardiovascular and Cerebrovascular Event [Time frame: November 2025 - December 2029]
  • Changes in Anti-Hypertensive Medication [Time frame: November 2025 - December 2029]

Eligibility criteria

Common Inclusion Criteria:

  • Adults aged ≥65 years with uncontrolled hypertension
  • Stable regimen of blood pressure-lowering medication

Common Exclusion Criteria:

  • Hypertension due to secondary causes
  • Prior renal denervation treatment
  • Pregnancy
  • End-stage renal disease, dialysis, or kidney transplant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 2 centers
  • Henry Ford Hospital — Detroit
  • Henry Ford St. John Hospital — Detroit

Identifiers

NCT: NCT07231757 · RADIANCE CED

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗